Pulmonary aspergillosis (PA), a pulmonary fungal infection caused by Aspergillus spp., is a
concern for immunocompromised populations. Despite substantial research efforts …

Pulmonary infections have long represented one of the major threats to humans. These vary
from acute to chronic conditions, depending upon the underlying disease of the airways …

Purpose Itraconazole (ITZ) dry powders for inhalation (DPI) composed of nanoparticles (NP)
embedded in carrier microparticles were prepared and characterized. Methods DPIs were …

Pulmonary infections caused by Aspergillus species are associated with significant
morbidity and mortality in immunocompromised patients. Although the treatment of …

Cystic fibrosis (CF) patients are suffering from multiple often chronic endobronchial infection.
The stiff mucus in these patients represents a compartment, which cannot easily be reached …

Invasive pulmonary aspergillosis is a life threatening fungal infection mainly caused by
Aspergillus species. Available treatment strategy against pulmonary aspergillosis is having …

The incidence of fungal pulmonary infections is known to be on the increase, and yet there is
an alarming gap in terms of marketed antifungal therapies that are available for pulmonary …

Lung fungal infection is a critical health problem, particularly in immunocompromised
patients suffering from lung cancer, cystic fibrosis, HIV infection, etc. Due to rapid blood …

Pulmonary mycoses are associated with high morbidity and mortality. The current standard
treatment by systemic administration is limited by inadequate local bioavailability and …

Purpose Novel itraconazole (ITZ)-based dry powders for inhalation (DPI) were optimized for
aerodynamic and dissolution properties and contained excipients that are acceptable for …